DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Related Party Transaction

Note 12 - Related Party Transaction	9 Months Ended
Sep. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	*12.* Related Party Transaction During 2021, we have engaged a consulting firm owned by our Vice President of Regulatory Affairs to perform certain tasks supporting our quality and regulatory activities. The work is performed as required by us and all services are invoiced on an hourly basis with no minimum commitment. We terminated this agreement effective June 16, 2021. Total charges invoiced in the current year prior to termination were approximately $149,000.

Note 12 - Related Party Transaction

9 Months Ended

Sep. 30, 2021

12. Related Party Transaction

During 2021, we have engaged a consulting firm owned by our Vice President of Regulatory Affairs to perform certain tasks supporting our quality and regulatory activities. The work is performed as required by us and all services are invoiced on an hourly basis with no minimum commitment. We terminated this agreement effective June 16, 2021. Total charges invoiced in the current year prior to termination were approximately $149,000.